FINWIRES · TerminalLIVE
FINWIRES

Braze's AI Momentum Builds But H2 2027 Questions Remain, Oppenheimer Says

By

Braze (BRZE) is positioned for a favorable fiscal Q2 setup as demand for its AI-driven decisioning and orchestration products remain resilient despite broader concerns over software spending, Oppenheimer said in a Thursday note.

Oppenheimer expects fiscal Q2 revenue of $220 million, up 22% year over year, and adjusted EPS of $0.15, with research checks pointing to potential upside to estimates, the note said.

The analysts said fiscal Q2 current remaining performance obligations will be a key indicator of sustained growth acceleration, although comparisons may become tougher in fiscal H2 2027 as Braze laps the OfferFit acquisition.

Meanwhile, the analysts flagged potential margin pressure from additiona services capacity needed to support Decisioning Studio's ramp, noting that strong AI product demand could be offset by higher services requirements that weigh on gross margins.

Oppenheimer maintained its outperform rating on the stock, while raising its price target to $36 from $30.

Shares of the company were up more than 9% in Thursday trading.

Price: $33.66, Change: $+2.85, Percent Change: +9.23%

Related Articles

Wire

Update: Magellan Financial Group Fiscal 2026 Operating Earnings, Revenue Down; Shares Fall 12%

(Updates to add stock movement in the headline and the last paragraph)Magellan Financial Group (ASX:MFG) logged AU$0.828 in operating earnings per share for fiscal 2026, compared with AU$0.898 a year ago, a Thursday filing showed.For the 12 months ended June 30, revenue and other income was AU$195.6 million versus AU$318.9 million previously, the Australia-listed financial services firm added.The board declared a final dividend of AU$0.255 per share, payable Sept. 16 to shareholders on record as of Sept. 2. A year ago, the company paid a final dividend AU$0.259 per share and special dividend of AU$0.21 per share.The board has revised the group's dividend policy from fiscal 2027, targeting a payout ratio of 60% to 90% of operating profit after tax.The company's shares fell 12% in recent Thursday trade.

ASX:MFG
Wire

Tenable to Join S&P SmallCap 600 Index

Tenable (TENB) will join the S&P SmallCap 600 index before market open on Aug. 31, the S&P Dow Jones Indices said in a late Wednesday statement.Tenable will replace Leggett & Platt (LEG), which is being acquired by Somnigroup International (SGI), according to the statement.

$LEG$SGI$TENB
Wire

NeoGenomics Wins Expanded Medicare Coverage for RaDaR ST Immunotherapy Monitoring

NeoGenomics (NEO) said its RaDaR ST molecular residual disease assay received expanded Medicare coverage to include immunotherapy response monitoring for patients with late-stage solid tumors.The determination from the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program is the third Medicare-covered indication for RaDaR ST, NeoGenomics said Wednesday in a statement.The coverage allows use of the assay to monitor response to immune-checkpoint inhibitor therapy, and NeoGenomics said it has two additional RaDaR ST submissions pending.NeoGenomics shares rose 2.1% in after-hours trading.

$NEO